Consistently, a tumor-suppressive role of AMPK was reported in vitro and in vivo settings, whereby AMPK pharmacological activation was shown to impact CSC features and metastatic potential of TNBC [46, 60, 61]. This evidence concerns the gene PRKAA1 and neoplasm.